FPT-SOFTWARE
1.2.2023 09:01:43 CET | Business Wire | Press release
FPT Software Europe, a subsidiary of FPT Software - leading technology and IT service provider headquartered in Vietnam, has recently announced its strategic partnership with Covestro AG (Covestro). As a leading global manufacturer of polymer materials, Covestro is included in DAX stock market index among major German companies trading on the Frankfurt Stock Exchange.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005414/en/
FPT Tower – FPT Corporation’s head quarter in Hanoi, Vietnam (Photo: Business Wire)
Entering a multi-year agreement with Covestro, FPT Software Europe is leveraging its in-depth experience, comprehensive services and best-shore model to support the DAX-listed group in the migration of 290 applications to the Amazon Web Services (AWS) cloud platform, thereby accelerating its digital transformation journey.
Starting signal for the next generation of IT infrastructure
Within the next few years, FPT Software Europe will accompany Covestro's entire transformation process. Starting with the assessment of customer requirements, the cloud experts analyze the chemical giant's legacy systems; design and implement solutions adapted to the AWS infrastructure. FPT Software Europe's core tasks in the migration process include refactoring legacy applications to preserve their functionality in the new ecosystem while leveraging the full potential of the new platform for the customer. By moving to AWS, Covestro AG is setting itself the goal of creating greater security for productive systems and business-critical workloads. Furthermore, by cloud migration, the company achieves additional benefits such as on-demand scalability of resources, increased productivity, and reduced capital and operating costs. With the move to the cloud, Covestro is laying the foundation for further digital transformation initiatives.
DAX company benefits from cloud migration expertise
FPT Software leverages its best-shore model, which is a mix of off shore, nearshore and onsite delivery to enable fast and cost-efficient processes to serve its customers like Covestro. As an AWS Advanced Partner with 600 highly qualified, certified AWS experts and around 20,000 highly trained IT specialists, FPT Software is able to implement the project in the shortest possible time and with the highest quality.
"As part of our promise to help Covestro accelerate its cloud migration, we have rapidly assembled project teams of cloud experts who work closely with the group's contacts on a day-to-day basis," said Le Hai, CEO of FPT Software Europe. "With the combined expertise of 600 certified AWS and 300 certified Microsoft experts, as well as thousands of other developers, FPT Software Europe is always ready to help European enterprises drive large-scale cloud projects and lay a solid foundation for broader digital transformation initiatives."
Through its partnership with FPT Software Europe, Covestro benefits from the comprehensive expertise of the Vietnamese IT service provider, which has already successfully implemented extensive cloud migration and digital transformation projects for major corporations like Schaeffler, RWE, Innogy and E.On.
FPT Software Europe and Covestro are discussing about further future joint projects in other areas such as managed services, cloud services with advanced application development and SAP implementation services.
About FPT Software Europe
FPT Software Europe, headquartered in Essen, Germany, is part of global technology and IT services provider FPT Software with 25,500 employees and revenue of more than $632.5 million. A pioneer in digital transformation, the company offers world-class services in Smart factory, Digital platforms, RPA (robotic process automation), Artificial Intelligence (AI), IoT (Internet of Thing), Data analytics, Mobility, Cloud, Managed services and Testing. FPT Software serves more than 1,000+ customers worldwide, 85 of which are Fortune Global 500 companies in the industries of Aerospace & Aviation, Manufacturing & Automotive, Banking Finance Insurance, Logistics & Transportation, Healthcare & Life Sciences, Retail, Utilities & Energy, and more. For more information, visit: www.fpt-europe.de.
About Covestro
Covestro is one of the world's leading manufacturers of high-quality plastics and their components. With its innovative products and processes, the company contributes to greater sustainability and quality of life in many areas. Covestro supplies global customers in key industries such as mobility, construction and housing, and electrical and electronics. In addition, Covestro's polymers are used in areas such as sports and leisure, cosmetics, healthcare and in the chemical industry itself.
The company is fully aligned with the circular economy and aims to become climate neutral by 2035 (Scope 1 and 2). In fiscal 2021, Covestro generated sales of €15.9 billion. As of the end of 2021, the company manufactures are presenting in 50 locations worldwide and employs around 17,900 people (full-time positions).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005414/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom